3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
24
Neoplasms
14
Melanoma
9
Endometrial Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Cholangiocarcinoma
6
Stomach Neoplasms
4
Recurrence
4
Carcinoma
4
Biliary Tract Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Paraganglioma, Extra-Adrenal
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Liver Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, Hurthle cell
1
Interventions
Gemcitabine
79
Cisplatin
56
pembrolizumab
32
Paclitaxel
28
Carboplatin
24
Docetaxel
19
Radiotherapy
17
Mitomycin
16
Doxorubicin
15
atezolizumab
14
BCG Vaccine
14
Nivolumab
13
Cystectomy
13
Filgrastim
11
vinflunine
10
Methotrexate
10
Vinblastine
9
Fluorouracil
9
5-aminolevulinic acid hexyl ester
9
Sunitinib
7
Early Intervention, Educational
7
durvalumab
6
avelumab
6
Taxes
6
Methods
6
Cystoscopy
6
Albumin-Bound Paclitaxel
6
enfortumab vedotin
5
Trastuzumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urinary Bladder Neoplasms
×
lenvatinib
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled